Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ISM8969 tablets or placebo

Phase 1

IInSilico Medicine Hong Kong Limited

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Obese Adult Participants at Risk of Cardiovascular DiseaseRecruiting

Obese Adult Participants at Risk of Cardiovascular DiseasePhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Obese Adult Participants at Risk of Cardiovascular Disease

NCT07581431

Clinical

Trials by Indication[1]

Obese Adult Participants at Risk of Cardiovascular Disease1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of ISM8969 in Healthy Adult and Elderly Participants and Obese Adult Participants at Risk of Cardiovascular Disease

Recruiting·IInSilico Medicine Hong Kong Limited·Phase 1·NCT07581431·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ISM8969 tablets or placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ISM8969 tablets or placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — InSilico Medicine Hong Kong Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: IInSilico Medicine Hong Kong Limited

Related News